The differentiating activity of these compounds in the presence of UV-A irradiation was associated with a dramatic induction of accumulation of the α-like α-globin and ζ-globin mRNA and the β-like ε-globin and γ-globin mRNA sequences. Of particular interest is our finding that erythroid induction and accumulation of γ-globin mRNA can be also obtained with psoralen plus UVA induced photolysis products. It will be of interest to identify and characterize the active products involved. This work was supported by the Associazione Veneta per la Lotta

alla Talassemia (AVLT) of Rovigo, by Fondazione Telethon (Contract GGP010214) and by Fondazione CARIPARO. R.G. is funded by FP7 THALAMOSS Project. “
“Estrogen receptor find more (ER) is overexpressed in more than 60% of human breast cancers. These ER-positive cancer patients

are commonly treated with an anti-estrogenic therapy such Selleckchem Abiraterone as tamoxifen (TAM) (Kim et al., 2011). Unfortunately, 30% of the ER-positive cancer patients who had received TAM treatment did not show improvement and died from the disease (Early Breast Cancer Trialists, 2005 and Chang, 2012). The mechanism underlying the acquisition of TAM resistance in ER-positive breast cancer has been of great interest to many investigators. The proposed mechanisms to date include the loss of ERα expression (Riggins et al., 2007), a mutation in the ERα (Zhang et al., 1997), higher expression of ERβ than ERα (inhibitors Speirs et al., 1999), variations in the CYP2D6 gene that cause lower plasma concentrations of effective TAM metabolites (Stearns et al., 2003), overexpression of an ER co-activator, amplified in breast cancer 1 (AIB1), which is also known as a steroid receptor co-activator 3 (SRC3) (Osborne et al., 2003, Zhao et al., 2009 and Zwart et al., 2011), reduction of co-repressor, NcoR, activity (Lavinsky et al., 1998) and the influences of cellular kinase signal transduction pathways through cross-talk between ER and epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2)/insulin-like

growth factor receptor (IGFR) (Ring these and Dowsett, 2004). Among the reported mechanisms underlying the acquisition of TAM resistance, HER2 overexpression-related mechanisms are summarized as follows. AIB1 is functionally activated by mitogen-activated protein kinase (MAPK), the activation of which is induced by HER2 signaling in tumors (Osborne et al., 2003 and Hurtado et al., 2008). HER2-mediated activation of MAPK induces phosphorylation of the serine118 residue in the AF-1 region of ER, which results in ligand-independent constitutive activation of ER (Bunone et al., 1996). Experimental evidence showed that HER2 overexpression may be the primary mechanism of TAM resistance; when HER2-transfected MCF-7 breast cancer cells were implanted into ovariectomized nude mice, tumor growth continued during TAM treatment (Benz et al.